Investment Rating - The investment rating for the company is "Hold" [1] Core Views - The company's revenue decreased by 11.5% year-on-year in 2023, totaling 8.79 billion yuan, while the net profit attributable to shareholders increased by 8.4% to 1.12 billion yuan [1][12] - In Q1 2024, the company achieved a revenue of 2.31 billion yuan, representing a year-on-year growth of 11.7%, and a net profit of 270 million yuan, up 36% year-on-year [1][12] - The company is focusing on optimizing its business structure, which has led to a decline in revenue but an improvement in profit margins [2][11] Summary by Sections Financial Performance - In 2023, the company reported a revenue of 8.79 billion yuan, down 11.5% year-on-year, with a net profit of 1.12 billion yuan, up 8.4% [1][12] - Q4 2023 revenue was 3.01 billion yuan, down 6% year-on-year, while net profit increased by 53.5% to 320 million yuan [1] - For Q1 2024, revenue was 2.31 billion yuan, up 11.7% year-on-year, with net profit also increasing by 36% [1][12] Business Structure and Revenue Sources - The decline in revenue is attributed to reduced demand in Europe and the US, along with the company's decision to abandon lower-margin businesses [2] - The company sold 13.46 million units of cleaning and health appliances, down 7.4% year-on-year, while sales of gardening tools and components increased by 2.5% to 132.76 million units [2] - Revenue from exports was 5.83 billion yuan, down 6.5%, while domestic sales fell by 20.2% to 2.78 billion yuan [2] Profitability and Margin Improvement - The gross margin for 2023 improved by 2.6 percentage points to 25.6%, with cleaning and health appliances achieving a gross margin of 26.4% [11] - The company expects gross margins for cleaning and health appliances to improve to 26% in 2024 and further in subsequent years [7] - The net profit margin for 2023 increased by 1.7 percentage points to 12.7%, indicating enhanced profitability [11] Future Outlook - The company anticipates revenue growth of 15.8% in 2024, reaching approximately 10.18 billion yuan, with net profit projected to grow by 10.85% to 1.24 billion yuan [13] - EPS is expected to be 2.16 yuan in 2024, increasing to 3.02 yuan by 2026 [12][16]

Investment Rating - The investment rating for the company is "Hold" [1] Core Insights - The company reported a revenue of 430 million RMB in 2023, representing a year-on-year growth of 25%, while the adjusted net profit decreased by 3.6% to 74.4 million RMB [2] - The IP creation and operation business saw a significant revenue increase of 82.9% to 190 million RMB, driven by the commercial value of Jay Chou's IP and the monetization of the celebrity matrix through live streaming [2][3] - The company completed a placement to raise 220 million HKD, primarily for concert investments and building a metaverse ecosystem [3] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 430 million RMB, with a growth rate of 25% [4] - The adjusted net profit for 2023 was 74.4 million RMB, showing a decline of 3.6% [4] - Revenue projections for 2024-2026 are 674 million RMB, 961.8 million RMB, and 1.23 billion RMB, with growth rates of 56.7%, 42.7%, and 27.8% respectively [4][10] Business Segments - The IP creation and operation segment is expected to continue its growth momentum, with revenue projected to increase significantly in the coming years [3][8] - The new retail business maintained stable revenue of 240 million RMB in 2023, with a focus on expanding public domain channels [2][3] Future Outlook - The company plans to launch new IP-related projects and collaborations, including video ringtones and upcoming variety shows [3] - The expected adjusted net profits for 2024-2026 are 140 million RMB, 210 million RMB, and 270 million RMB, indicating strong growth potential [4][10]

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company achieved a revenue of 81.556 billion yuan in 2023, representing a year-on-year growth of 11.74%, and a net profit of 7.039 billion yuan, up 27.21% year-on-year. However, in Q1 2024, revenue dropped to 15.971 billion yuan, a decline of 22.02%, with a net loss of 0.483 billion yuan, down 118.70% year-on-year [2][11]. - The company has a strong presence in the overseas market, with 48% of its solar module shipments going abroad in 2023, contributing significantly to profitability. The gross margin for solar modules was 18.28%, an increase of 3.97 percentage points year-on-year [2][11]. - The company is expanding its N-type battery production capacity, which is expected to enhance efficiency and profitability in the future. The N-type battery production capacity exceeded 57 GW by the end of 2023, with a conversion efficiency of 26.3% [2][11]. Summary by Sections Financial Performance - In 2023, the company reported a total revenue of 81.556 billion yuan and a net profit of 7.039 billion yuan. The Q1 2024 revenue was 15.971 billion yuan, with a net loss of 0.483 billion yuan [2][11]. - The company’s gross margin for solar modules was 18.28% in 2023, with a forecasted decline in Q1 2024 to 5.06% due to increased competition and lower delivery prices [2][11]. Production Capacity and Market Position - The company’s total production capacity exceeded 95 GW by the end of 2023, with N-type battery capacity leading the market. The company is also constructing new facilities in Vietnam and the United States to support its overseas market strategy [2][11]. - The company plans to increase its production capacity to over 100 GW for silicon wafers, batteries, and modules by the end of 2024, enhancing its vertical integration [2][11]. Profit Forecast - The company is expected to face challenges in Q1 2024 due to industry competition and pricing pressures. However, profitability is anticipated to recover as production capacity ramps up and costs are controlled. Projected net profits for 2024, 2025, and 2026 are 2.840 billion yuan, 4.398 billion yuan, and 7.626 billion yuan, respectively [2][11].

医药行业2023年年报及2024年一季报总结 业绩低点已过，看好后续医药行情 西南证券研究发展中心 2024年5月 分析师：杜向阳 执业证号：S1250520030002 电话：021-68416017 邮箱：duxy@swsc.com.cn 核心观点  我们选取了314家医药上市公司（包含科创板），2023年收入总额21786亿元（+6%）；归母净利润1815.9亿元（-2.4%） ；扣非归母净利润1674.7亿元（-0.9%），分别占申万医药全成分比例是：87%、115%、125% ，主要剔除了在2022-2023 年提取巨额商誉减值损失的企业、ST类和2023年以后上市的公司。剔除新冠相关业务数据，2023年收入总额21680亿元（ ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance in 2023 met expectations, with a revenue of 2.33 billion yuan, a year-on-year decrease of 3.2%, and a net profit attributable to shareholders of 610 million yuan, a year-on-year increase of 4.3% [2] - In Q1 2024, the company achieved a revenue of 440 million yuan, a year-on-year increase of 67%, and a net profit attributable to shareholders of 120 million yuan, a year-on-year increase of 116.3% [2] - The company is expected to experience a growth inflection point in plasma collection due to the establishment of new plasma stations [2] Summary by Sections Financial Performance - In 2023, the company's quarterly revenues were 260 million, 450 million, 670 million, and 950 million yuan respectively, showing a significant recovery in the latter half of the year [2] - The overall gross profit margin for 2023 was 51.5%, with a net profit margin of 26.3%, reflecting a year-on-year increase of 1.9 percentage points [2] Growth Drivers - The company has received approval for eight new plasma collection stations since August 2022, which is expected to accelerate plasma collection in 2024 [2] - The estimated net profit for 2024-2026 is projected to be 780 million, 890 million, and 1.02 billion yuan respectively, with corresponding valuations of 28x, 25x, and 21x [2] Market Position - The company has a total market capitalization of 21.84 billion yuan and a total asset value of 8.72 billion yuan [5] - The company's earnings per share (EPS) for 2023 is 0.84 yuan, with a projected increase to 1.39 yuan by 2026 [3][10]

绝味食品（603517）2023 年报&2024 年一季报点评 附表：财务预测与估值 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------|-------|----------------------------------|-------|----------------------------------------|--------------------------------------|---------|----------------------------------|---------------------|--------| | [Table_ProfitDetail] 利润表（百万元） | 2023A | 2024E | 2025E | 2026E | 现金流量表（百万元） | 2023A | 2024E | 2025E | 2026E | | 营业收入 | | 7261.33 7932.09 8656.78 9320.00 | | ...

基础数据 [Table_BaseData] 总股本(亿股) 2.27 流通 A 股(亿股) 2.27 52 周内股价区间(元) 22.93-41.2 总市值(亿元) 74.07 总资产(亿元) 30.33 每股净资产(元) 9.09 3.7 亿元，维持"买入"评级。 相关研究 [Table_Report] 1. 卫光生物（002880）：收入增长符合预期， 三季度研发投入有所增长 (2023-11-05) 2. 卫光生物（002880）：产品收入大幅增长， 全年业绩可期 (2023-09-03) [Table_Summary 事件：公司发布] 2023年报&2024年一季报，2023年实现收入 10.5亿元，同比 +57%，实现归母净利润 2.2亿元，同比+86.1%，扣非归母净利润 2.1亿元，同 比+95.9%；2024年一季度收入 2.3亿元，同比+8.5%，归母净利润 4683万元， 同比+2.4%，扣非归母净利润 4552 万元，同比+1.3%。 2023年采浆 517吨，纤原收入增长超出整体业务增速。公司 2023年采浆 517 吨，同比增长超过 10%。全年人白、静丙、纤原、狂免 2023 年收 ...

[Table_StockInfo] 持有 2024年 05月 09日 （维持） 证券研究报告•2023年年报及2024年一季报点评 当前价： 21.78元 天合光能（688599） 电力设备 目标价： ——元（6个月） 24Q1 业绩超预期，盈利表现优于同行 投资要点 西南证券研究发展中心 [T ab事le件_S：u公mm司a2ry0]2 3年实现营业收入1133.92亿元，同比增长33.32%；实现归母 净利润 55.31亿元，同比增长 50.26%。2024Q1实现营业收入 182.56亿元， [分Ta析bl师e_：Au韩th晨or ] 同比下降14.37%；实现归母净利润5.16亿元，同比下降70.83%。 执业证号：S1250520100002 电话：021-58351923  组件、分布式、支架、储能业务齐头并进，电站开发业务取得超预期增长。2023 邮箱：hch@swsc.com.cn 年公司组件出货量为65.21GW，同比增长超过51.3%。其中用于电站、电站工 分析师：敖颖晨 程建设管理及系统产品的组件量为 10.72GW。光伏组件业务实现营业收入 764.49亿元，同比增长21.15%； ...

[Table_StockInfo] 买入 2024年 05月 09日 （维持） 证券研究报告•2023年报及2024年一季报点评 当前价： 25.20元 久立特材（002318） 钢铁 目标价： ——元（6个月） 高端产品持续放量，盈利能力不断提升 投资要点 西南证券研究发展中心 [T ab事le件_S：u公m司m发ary布] 2023年报和2024年一季报，公司2023年实现营收85.7亿元， [分Ta析bl师e_：Au黄th腾or飞] 同比+31.1%；归母净利润14.9亿元，同比+15.6%；扣非归母净利12.2亿元， 执业证号：S1250523070010 同比-5.1%。2024Q1，公司实现营收23.9亿元，同比+42.3%；归母净利润3.3 电话：13651914586 亿元，同比+41%；扣非归母净利3.4亿元，同比+51.4%。 邮箱：htengf@swsc.com.cn  行业层面：不锈钢管分化严重-高端产品享有溢价。产量：我国不锈钢管产能约 [T相ab对le指_Q数u表ot现eP ic] 300万吨，产品分化严重，整体呈现低端过剩，高端紧缺的局面。需求：不锈钢 久立特材 沪深300 ...

[Table_StockInfo] 买入 2024年 05月 08日 （维持） 证券研究报告•2023年年报及24年一季报点评 当前价： 11.42元 恺英网络（002517） 传媒 目标价： ——元（6个月） 业绩表现亮眼，关注后续新游上线进展 投资要点 西南证券研究发展中心 [T a事ble件_S：u公mm司a发ry布] 2023年年报及2024年一季报，23年公司实现收入43亿元， [分Ta析bl师e_：Au刘th言or ] 同比+15.3%，归母净利润14.6亿元，同比+42.6%；扣非归母净利润13.5亿元， 执业证号：S1250515070002 同比+41.3%；单季度来看，单 Q4实现营收 12.7亿元，同比+40.6%，归母净 电话：023-67791663 利润 3.8亿元，同比+240.8%。24Q1公司实现营收13.1亿元，同比+36.9%。 邮箱：liuyan@swsc.com.cn 归母净利润4.3亿元，同比+47.1%，扣非归母净利润4.2亿元，同比+48.4%， 分析师：苟宇睿 业绩整体高于此前预期，继续保持良好发展势头。 执业证号：S1250524030001  三大板块 ...